Delving into the Latest Updates on BGP-15 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

HSP stimulants(Heat-shock protein stimulants), PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), Insulin sensitizers

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Diabetes Mellitus, Type 2Muscular Dystrophy, Duchenne

Inactive Indication

Beta Ketothiolase DeficiencyChemotherapy-induced damageCOVID-19+ [3]

Originator Organization

N-Gene

Active Organization

N-Gene

Inactive Organization

N-Gene Research Laboratories, Inc.

Allos Therapeutics, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC14H22N4O2

InChIKeyMVLOQULXIYSERZ-UHFFFAOYSA-N

CAS Registry66611-38-9

View All Structures (2)

This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone in patients with Type 2 Diabetes Mellitus.

Start Date01 Oct 2010

Sponsor / Collaborator

N-Gene Research Laboratories, Inc.

[+6]

100 Clinical Results associated with BGP-15

Login to view more data

100 Translational Medicine associated with BGP-15

Login to view more data

100 Patents (Medical) associated with BGP-15

Login to view more data

76

Literatures (Medical) associated with BGP-15

01 Aug 2024·Computers in Biology and Medicine

CAS3D: 3D quantitative morphometry on Second Harmonic Generation image volumes from single skeletal muscle fibers

Article

Author: Ritter, Paul ; Mnuskina, Sofia ; Schneidereit, Dominik ; Nübler, Stefanie ; Friedrich, Oliver ; Mühlberg, Alexander ; Kreiss, Lucas ; Bauer, Julian ; Larsson, Lars ; Schürmann, Sebastian ; Cacciani, Nicola

The CAS3D image processing method intuitively applies a combination of Fourier space and real space 3D analysis algorithms to volumetric images of single skeletal muscle fiber Myosin II Second Harmonic Generation (SHG) XYZ image data. Our developed tool automatically quantifies the myofibrillar orientation in muscle samples by determining the cosine angle sum of intensity gradients in 3D (CAS3D) while determining the mean sarcomere length (SL) and sample orientation. The expected CAS3D values could be reproduced from ideal artificial data sets. Applied random noise in artificial images lowers the detected CAS3D value, and for noise levels below 20%, the correlation can be approximated by a linear function with a slope of -0.006 CAS3D/noise%. The deviations in SL and orientation detection were determined on ideal and noisy artificial data sets and were statistically indistinguishable from 0 (null hypothesis t-test P > 0.1). The software was applied to a previously published data set of single skeletal muscle fiber volumetric SHG image data from a rat intensive care unit (ICU) model of ventilator-induced diaphragm dysfunction (VIDD) with treatment regimens involving the small anti-inflammatory molecules BGP-15, vamorolone, or prednisolone. Our method reliably reproduced the results of the previous work and improved the standard deviation of the cosine angle sum detection in all sample groups from a mean of 0.03 to 0.008. This improvement is achieved by applying analysis algorithms to the whole volumetric images in 3D in contrast to the previously common method of slice-wise XY analysis.

01 Aug 2024·Brain, Behavior, and Immunity

Response to comment on: BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy

Letter

Author: Liu, Qian ; Liu, Gong-Ping

A review.In this investigation, we discovered that BGP-15 can improve depressive-like behaviors (DLB) in mice by promoting PINK1/Parkin-dependent mitophagy, but the mechanism is not clear.In vitro studies revealed that BGP-15 interacts with mitochondrial proteins or lipids.It is hypothesized that the mechanism by which BGP-15 improves mitophagy may involve its mitochondrial targeting, warranting further investigation.

01 Aug 2024·Brain, Behavior, and Immunity

Commentary on the Article “BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy”

Article

Author: Chen, Haiyang ; Ren, Lu ; Shi, Liuqing

A polemic in response to Liu et al., 2024 (Brain Behav. Immun. 119, 648-664)is given.Liu et al. described potential role of BGP-15 as a neuroprotective agent in enhancing mitophagy and suppressing the activation of the NLRP3 inflammasome offers fresh perspective for the treatment of depression.The author after a thorough anal. of the study raised few queries and suggestions as follows:.While the paper mentions that BGP-15 acts through the PINK1/Parkin-dependent mitophagy pathway, the specific mol. mechanisms by which BGP-15 influences this pathway are not elaborated. Could future research provide more details on the interaction between BGP-15 and proteins involved in mitophagy.Given that BGP-15 has shown good tolerability in other clin. trials, have the authors considered applying it to clin. studies involving patients with depression The outcomes of such studies could significantly impact clin. practice.The study utilized male mice, but it is well-documented that gender differences exist in the prevalence and presentation of depression. Will future studies consider including female mice to assess the impact of gender on the effects of BGP-15.Besides mitophagy and the NLRP3 inflammasome mentioned in the paper, are there other biomarkers or pathways that might be associated with the antidepressant effects of BGP-15.Author impressed by the depth and quality of this research and look forward to the authors' perspectives on the above issues and believe that further research and discussion will enable us to fully understand the potential of BGP-15 in the treatment of depression.

100 Deals associated with BGP-15

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tachycardia, Sinus	Phase 3	HU	-	30 Sep 2020
Insulin Resistance	Phase 3	HU	N-Gene Research Laboratories, Inc.	04 Apr 2006
Diabetes Mellitus, Type 2	Phase 2	-	N-Gene	-
Muscular Dystrophy, Duchenne	Phase 2	-	N-Gene	-
Beta Ketothiolase Deficiency	Phase 1	HU	N-Gene Research Laboratories, Inc.	01 Oct 2010
Beta Ketothiolase Deficiency	Phase 1	US	N-Gene Research Laboratories, Inc.	01 Oct 2010
Beta Ketothiolase Deficiency	Phase 1	DE	N-Gene Research Laboratories, Inc.	01 Oct 2010
Chemotherapy-induced damage	Phase 1	HU	N-Gene Research Laboratories, Inc.	-
Reperfusion Injury	Phase 1	HU	-	-
COVID-19	Discovery	HU	-	26 Mar 2021